Pharmacogenetics and Individualized Therapy

This resource provides thorough coverage of pharmacogenetics and its impact on pharmaceuticals, therapeutics, and clinical practice. It opens with the basics of pharmacogenetics, including drug disposition and pharmacodynamics. The following section moves into specific disease areas, including cardiovascular, psychiatry, cancer, asthma/COPD, adverse drug reactions, transplantation, inflammatory bowel disease, and pain medication. Clinical practice and ethical issues make up the third section, with the fourth devoted to technologies like genotyping, genomics, and proteomics. In the fifth part, chapters discuss the impact of key regulatory issues on the pharmaceutical industry.

Preface vii

Contributors ix

1. Pharmacogenetics: A Historical Perspective 1
Ann K. Daly

Part I Pharmacogenetics: Relationship to Pharmacokinetics and Pharmacodynamics

2. Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes 15
Vita Dolžan

3. Pharmacogenetics of Phase II Drug Metabolizing Enzymes 81
Ingolf Cascorbi

4. Pharmacogenetics of Drug Transporters 101
Henriette E. Meyer zu Schwabedissen, Markus Grube, and Heyo K. Kroemer

5. Pharmacogenetics of Drug Targets 149
Ann K. Daly and Maria Arranz

Part II Pharmacogenetics: Therapeutic Areas

6. Cardiovascular Pharmacogenetics 185
Bas J. M. Peters, Anthonius de Boer, Tom Schalekamp, Olaf H. Klungel, and Anke-Hilse Maitland-van der Zee

7. Pharmacogenetics in Psychiatry 215
Evangelia M. Tsapakis, Sarah Curran, Ruth I. Ohlsen, Nora S. Vyas, Katherine J. Aitchison, and Ann K. Daly

8. Pharmacogenetics in Cancer 251
Sharon Marsh

9. Pharmacogenetics of Asthma and COPD 271
Ellen S. Koster, Jan A. M. Raaijmakers, Anke-Hilse Maitland-van der Zee, and Gerard H. Koppelman

10. Pharmacogenetics of Adverse Drug Reactions 295
Ann K. Daly, Martin Armstrong, and Munir Pirmohamed

11. Pharmacogenomics of Inflammatory Bowel Diseases 323
Alexander Teml, Susanne Karner, Elke Schaeffeler, and Matthias Schwab

12. Pharmacogenetics of Pain Medication 353
Jörn Lötsch

Part III Pharmacogenetics: Implementation in Clinical Practice

13. Ethical and Social Issues in Pharmacogenomics Testing 377
Susanne Vijverberg, Toine Pieters, and Martina Cornel

Part IV Developments in Pharmacogenetic Research

14. High-Throughput Genotyping Technologies for Pharmacogenetics 403
Beatriz Sobrino and Angel Carracedo

15. Developments in Analyses in Pharmacogenetic Datasets 415
Alison A. Motsinger-Reif

Part V Pharmacogenetics: Industry and Regulatory Affairs

16. Applications of Pharmacogenetics in Pharmaceutical Research and Development 439
Daniel K. Burns and Scott S. Sundseth

17. Role of Pharmacogenetics in Registration Processes 461
Myong-Jin Kim, Issam Zineh, Shiew-Mei Huang, and Lawrence J. Lesko

Part VI Conclusions

18. Pharmacogenetics: Possibilities and Pitfalls 479
Anke-Hilse Maitland-van der Zee and Ann K. Daly

Index 485

“This is a well-written book that I highly recommend to anyone interested in any aspect of personalized medicine.” (Doody’s, 24 August 2012)

ANKE-HILSE MAITLAND-VAN DER ZEE, PHD, is Associate Professor of Pharmacogenetics/Pharmacogenomics at Utrecht University, the Netherlands.

ANN K. DALY, PHD, is Professor of Pharmacogenetics at Newcastle University, UK.

The one-stop reference to pharmacogenetics and its impact on pharmaceuticals, therapeutics, and clinical practices

Pharmacogenetics and Individualized Therapy offers thorough coverage of the study of the genetic determinants of drug response at the single gene level—and its impact on pharmaceuticals, therapeutics, and clinical practice. Providing an overview of the molecular basis of pharmacogenetics, the book helps readers understand the implications of genetic variability on pharmacokinetics and pharmacodynamics, as well as other aspects such as adverse drug reactions. Providing coverage of specific disease areas, including cardiovascular concerns, cancer and asthma/COPD, transplantation, and pain medication, the book also looks at the clinical practices, along with the psychiatric and ethical issues that have come to dominate conversation about pharmacogenetics.

The technological applications of pharmacogenetics, including genotyping, drug disposition (metabolism and enzymes), and the impact of this research on the pharmaceutical industry and regulatory matters are all addressed in chapters by internationally recognized leaders from both academia and industry.

Including chapters on specific therapeutic areas and clinical aspects, Pharmacogenetics and Individualized Therapy helps readers, whether they're students or researchers, to understand the implications of genetic variability on pharmacokinetics and pharmacodynamics.